https://www.wolterskluwer.com/en/expert-insights/biosimilar-insulin
Biosimilar insulin: Can interchangeability help overcome diabetes treatment barriers? | Wolters...
First biosimilar interchangeable insulin helps pharmacists improve medication adherence by lowering costs, addressing stigma for diabetes patients.
biosimilar insulindiabetes treatmentinterchangeabilityhelpovercome
https://kffhealthnews.org/morning-breakout/mylan-launches-semglee-a-biosimilar-insulin-at-discounted-price/
Mylan Launches Semglee, A Biosimilar Insulin, At Discounted Price - KFF Health News
Sep 1, 2020 - Other pharmaceutical companies in the news include Vir, GlaxoSmithKline, Xeris and Purdue Pharma.
biosimilar insulin
https://www.endocrine.org/advocacy/society-letters/2020/final-group-letter-supporting-asp8
Letter to Congressional Leadership About Biosimilar Insulin | Endocrine Society
We joined a sign on letter urging Congressional leaders to include ASP+8% for biosimilars in any year-end package.
biosimilar insulinlettercongressionalleadershipendocrine
https://pmc.ncbi.nlm.nih.gov/articles/PMC6313268/
Biosimilar and Follow-on Insulin: The Ins, Outs, and Interchangeability - PMC
Objective: To provide an overview of the differences between biosimilars and generics, and to summarize regulatory requirements and outstanding issues related...
follow onbiosimilarinsulinoutsinterchangeability
https://www.prnewswire.com/news-releases/semglee-approval-can-provide-unexplored-opportunities-to-us-insulin-biosimilar-market-301357962.html
Semglee Approval Can Provide Unexplored Opportunities To US Insulin Biosimilar Market
/PRNewswire/ -- Over the past few years, the adaptability of biosimilars is increasing continuously in US and recent trends are indicating towards the rapid...
semgleeapprovalprovideunexplored
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-immunogenicity-considerations-biosimilar-and-interchangeable-insulin-products
Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products | FDA
Guidance for Industry - Biosimilars
clinicalimmunogenicityconsiderationsbiosimilarinterchangeable